Abstract
Introduction
The skeletal muscle accounts for approximately 80% of insulin-stimulated glucose disposal and, therefore, plays a key role in development and progression of insulin resistance and type 2 diabetes mellitus [1] . In the obese state, a reduced adipose tissue lipid buffering capacity increases lipid supply to other tissues such as the skeletal muscle [2] . In addition, impairments in postprandial fatty acid uptake, storage, and oxidation may contribute to intramuscular accumulation of lipid intermediates, which has been associated with insulin resistance [3, 4] .
Results from several studies suggest that the gut microbiota has potential to impact the physiology of the host and may thereby contribute to insulin resistance [5] [6] [7] [8] [9] [10] . For example, skeletal muscle in germ-free mice was characterized by elevated levels of phosphorylated 5 ′ -AMP-activated protein kinase (AMPK) and its downstream targets involved in fatty acid oxidation (i.e. acetyl CoA carboxylase) [5] . Upon transplantation of obese porcine microbiota into germ-free mice, muscle fiber size decreased, and lipogenesis in the mouse skeletal muscle was enhanced [11] . Additionally, the gut hormone glucagon-like peptide (GLP-1) has been found to increase microvascular recruitment and basal glucose uptake in the muscle via a nitric oxide-dependent mechanism [8] . Moreover, short-chain fatty acids (SCFA) that are produced by the gut may have direct effects on peripheral substrate metabolism by binding to their receptors (FFA2 and 3) that are expressed in skeletal muscle [12, 13] or indirect effects via FFA2 binding in adipose tissue, thereby suppressing insulin signaling in adipocytes and increasing the lipid supply to skeletal muscle [14] [15] [16] .
Taken together, these studies suggest that the gut microbiota-skeletal muscle cross-talk might be involved in substrate metabolism and insulin sensitivity [9, 10] . To our knowledge, only one human study has explored the effects of gut microbiota modifications on skeletal muscle, showing that a prebiotic formulation improved handgrip strength and muscle exhaustion in an older population [17] . The effect on skeletal muscle substrate metabolism and insulin sensitivity under physiological conditions in humans is not known. We hypothesized that changes in the gut microbiota composition alter skeletal muscle metabolism in humans.
We have recently shown that 7-day treatment with the narrow-spectrum antibiotic vancomycin (VANCO) reduced the abundance of Gram-positive Firmicutes that are, amongst others, involved in SCFA metabolism, and increased the abundance of Gram-negative Proteobacteria [18] . In addition, VANCO significantly altered plasma SCFA concentrations and the bile acid (BA) profile [18] . Here, we investigated whether these VANCO-induced effects translate into changes in skeletal muscle blood flow and metabolite fluxes across forearm muscle in obese men with impaired glucose metabolism.
Material and Methods

Experimental Procedures
The present study investigated the effects of antibiotic treatment on skeletal muscle substrate metabolism and postprandial insulin sensitivity in 40 obese males with impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) [18] . In this randomized, double-blind study with a 3-armed parallel design, participants received either 500 mg/day amoxicillin (AMOX, broad-spectrum), vancomycin (VANCO, narrowspectrum) or placebo for 7 consecutive days. This study was performed in a subgroup of a larger clinical trial, in which we investigated the impact of antibiotic treatment on microbiota composition and tissue-specific insulin sensitivity [18] . The inclusion and exclusion criteria have been reported in detail previously [18] . This study was approved by the local Medical Ethical Committee, and all participants gave written informed consent. All procedures were according to the declaration of Helsinki (revised version, October 2008).
Study Procedures
Before and after the intervention, forearm muscle metabolism and blood flow were studied in the fasting state and for 4 h after consumption of a high-fat mixed meal (2.6 MJ, consisting of 61 energy% (E%) fat, 33 E% carbohydrate, 6 E% protein). To this end, catheters were inserted into the superficial dorsal hand vein, which was heated in a hot box (55 ° C) to allow arterialized venous blood sampling, and in a deep antecubital vein of the contralateral forearm to sample venous blood. Blood samples were taken simultaneously from these catheters to determine arterio-venous concentration differences of glucose, insulin, lactate, free fatty acids (FFA) and triacylglycerol (TAG), using previously described assays [18] . Forearm blood flow (FBF) was determined at using venous occlusion plethysmography to calculate substrate fluxes across forearm muscle [19] . Using FBF, hematocrit and arterialized and deep-venous plasma concentrations, we calculated the net forearm muscle uptake or release of metabolites. A positive flux indicates net uptake across forearm muscle, whereas a negative flux indicates net release into the circulation [19, 20] .
For microbiota profiling, DNA was isolated from fecal samples, and subsequently used for phylogenetic profiling using the HIT-Chip phylogenetic microarray [21] as described before [18] .
Statistical Analysis
To be able to detect a differential skeletal muscle lipid handling, n = 12 per intervention group has shown to have sufficient power in previous studies [22] . To account for possible drop-outs and block randomization, we decided to include the first 40 participants of the clinical trial for this sub-study in order to reach at least n = 12 per group. Repeated-measures ANOVA (SPSS 20.0 for Macintosh (IBM, Armonk, NY, USA)) was used to determine the time × treatment interaction between groups followed by post-hoc Student's t-test for subgroup analysis. Data are expressed as mean ± standard error of the mean. p < 0.05 was considered to be statistically significant.
For HIT-Chip analysis, log10-transformed signals were used as a proxy for bacterial logarithmic abundance. To determine which bacterial groups were significantly different in relative abundance before and after treatment within each group, a paired Wilcoxon test was used. False discovery rate (FDR) was controlled by applying Benjamini-Hochberg correction for multiple testing. Diversity of the microbiota was quantified based on non-logarithmized HIT-Chip oligo-level signals by inverse Simpson's index using the Vegan package [23] . A significance level of FDR < 0.05 was considered significant. Statistical analyses were performed using SPSS 20.0 for Macintosh and R 3.3.2.
Results
No serious adverse events of the antibiotic treatment were reported. At baseline, body weight, BMI, and body fat distribution did not differ between groups ( table 1 ) . Furthermore, baseline fasting plasma glucose, insulin, lactate, glycerol, TAG, and FFA concentrations were comparable between groups ( table 1 , fig. 1 ). Seven-day treatment with the narrow-spectrum antibiotic VANCO decreased the gut bacterial diversity and reduced the abundance of Gram-positive Firmicutes (supplemental fig. 1 [18] . VANCO treatment did not significantly affect fasting and postprandial (iAUC/min) circulating metabolite and insulin concentrations as compared to placebo (all p > 0.05).
Baseline fasting FBF was comparable between groups. Moreover, at baseline, postprandial FBF did not significantly increase after meal intake and was comparable between groups. VANCO treatment had no significant effect on baseline and postprandial FBF as . A positive flux indicates net uptake across forearm muscle whereas a negative flux indicates net release. compared to placebo ( fig. 1 ). Furthermore, we found no significant effects of VANCO on fasting and postprandial net forearm muscle glucose uptake, the release of lactate across forearm muscle, fasting and postprandial glycerol as well as FFA and TAG fluxes across forearm muscle as compared to placebo ( table 2 ) . In line with the lack of effect on the gut microbial profile (supplemental fig. 1 fig. 2 ).
Discussion
The present study demonstrated that antibiotic treatment for 7 days using VANCO or AMOX had no significant effects on fasting and postprandial forearm muscle substrate metabolism and postprandial insulin sensitivity in obese men with impaired glucose homeostasis. We [18] and others [24] have previously demonstrated that 7-day VANCO treatment affected microbial diversity and composition. These results were confirmed in the present study including obese men with impaired glucose metabolism. Briefly, the abundance of butyrateproducing species and species involved in BA dehydroxylation decreased following VANCO, whilst there was a compensatory increase of Gram-negative Proteobacteria and VANCOresistant bacilli. This was accompanied by a reduced conversion of primary to secondary BA and a lower production of SCFA in the gut [18] . Alterations in gut hormones and microbial products such as SCFA [8, 25] , have been suggested to underlie changes in skeletal muscle fat oxidation and substrate metabolism following gut microbiota manipulation. More specific, it has been suggested that the stimulation of fat oxidation in skeletal muscle might be under influence of gut-derived hormones and substrates such as SCFA and BA through metabolic pathways involving the phosphorylation of AMPK [5] , which in turn regulates skeletal muscle glucose uptake [26] . However, the present study demonstrated that VANCO-induced changes in plasma SCFA and BA concentrations did not affect forearm muscle metabolism in humans. We found that VANCO treatment did neither influence systemic lipid overflow, i.e. fasting and postprandial TAG and FFA concentrations, nor postprandial glucose and insulin concentrations. Together with an unchanged postprandial forearm muscle glucose flux following VANCO treatment, these findings indicate that postprandial insulin sensitivity was not affected.
In line with unchanged microbial and metabolic profiles following AMOX treatment [18] , we found no significant effects of AMOX on forearm substrate metabolism in the present study.
Our data are in contrast to rodent studies showing that the gut microbiota exert effects on substrate and energy metabolism [6, 7, [27] [28] [29] [30] [31] . Although it has previously been suggested that antibiotic treatment may improve metabolic impairments in mice [27] [28] [29] [30] , a 4-day broad-spectrum antibiotic cocktail did not affect postprandial glucose metabolism in lean, healthy men [32] . Moreover, we have previously shown that whole-body insulin sensitivity, determined by the gold-standard hyperinsulinemic-euglycemic clamp, was not affected by 7-day antibiotic treatment [18] . Noteworthy, in rodent studies, animals were exposed to antibiotics in their drinking water for at least 4 weeks. Similarly, more prolonged treatment (4-6 weeks) with a higher dosage or a combination of antibiotics, increased body weight in endocarditis patients [33, 34] . Although these studies may indicate that long-term dysbalance in microbiota composition has more pronounced effects as compared to short-term manipulation, no significant changes in glucose and insulin concentrations as well as whole-body insulin sensitivity were found 8 weeks after cessation of VANCO treatment, despite a still considerably altered microbial composition as compared to pre-treatment [18] .
In conclusion, the present study demonstrated that, despite marked changes in gut microbiota composition following VANCO treatment, forearm substrate metabolism and postprandial glucose metabolism were not altered by 7-day antibiotic treatment in obese men with impaired glucose metabolism. Our data suggest that strategies targeting the gut microbiota (i.e. specific dietary interventions) may not be effective in improving metabolic health in obese humans. Further research should establish whether more prolonged manipulation of the gut microbiota, in a larger group of subjects, may induce changes in skeletal muscle substrate metabolism and thereby provides opportunities to improve metabolic health.
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